PMID- 1454818
OWN - NLM
STAT- MEDLINE
DCOM- 19930107
LR  - 20220408
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 89
IP  - 23
DP  - 1992 Dec 1
TI  - Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal 
      dopamine turnover in vivo.
PG  - 11347-51
AB  - Brain-derived neurotrophic factor (BDNF), a member of the nerve growth factor 
      (NGF)-related family of neutrophins, promotes the survival and differentiation of 
      cultured nigral dopamine neurons. Two-week infusions of BDNF were made above the 
      right pars compacta of the substantia nigra in adult rats. Systemic injection of 
      these animals with (+)-amphetamine, a dopamine-releasing drug, induced 3 or 4 
      body rotations per minute directed away from the nigral infusion site. Neither 
      supranigral NGF nor neocortical BDNF infusions induced rotational behavior. 
      Systemic injections of the postsynaptic dopamine receptor agonist apomorphine did 
      not induce rotations in these animals, demonstrating a presynaptic dopamine 
      neuron locus for BDNF action. In support of this, neostriatal levels of the 
      dopamine metabolite homovanillic acid (HVA) were elevated by 28%, and the 
      HVA/dopamine and dihydroxyphenylacetic acid (DOPAC)/dopamine ratios were elevated 
      by 56% and 34%, respectively, in the BDNF-infused brain hemisphere. BDNF 
      augmented striatal concentrations of HVA and DOPAC and the metabolite/dopamine 
      ratios to even greater extents after (+)-amphetamine injection, when peak 
      rotational effects occurred. Intrastriatal infusions of BDNF produced fewer 
      rotations per minute (1-2.5) after (+)-amphetamine and smaller elevations in HVA 
      and the HVA/dopamine ratio (15% and 30%, respectively) than after supranigral 
      delivery. Neither striatal dopamine, gamma-aminobutyric acid, nor acetylcholine 
      high-affinity uptake or the synthetic enzymes for these neurotransmitters was 
      altered by BDNF. These behavioral and neurochemical effects demonstrate an action 
      of BDNF on dopamine neurons in vivo and are consistent with a potential role for 
      BDNF in the treatment of Parkinson disease.
FAU - Altar, C A
AU  - Altar CA
AD  - Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591.
FAU - Boylan, C B
AU  - Boylan CB
FAU - Jackson, C
AU  - Jackson C
FAU - Hershenson, S
AU  - Hershenson S
FAU - Miller, J
AU  - Miller J
FAU - Wiegand, S J
AU  - Wiegand SJ
FAU - Lindsay, R M
AU  - Lindsay RM
FAU - Hyman, C
AU  - Hyman C
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Recombinant Proteins)
RN  - 102-32-9 (3,4-Dihydroxyphenylacetic Acid)
RN  - CK833KGX7E (Amphetamine)
RN  - N21FAR7B4S (Apomorphine)
RN  - VTD58H1Z2X (Dopamine)
RN  - X77S6GMS36 (Homovanillic Acid)
SB  - IM
MH  - 3,4-Dihydroxyphenylacetic Acid/metabolism
MH  - Amphetamine/pharmacology
MH  - Animals
MH  - Apomorphine/pharmacology
MH  - Behavior, Animal/*physiology
MH  - Brain-Derived Neurotrophic Factor
MH  - Cerebral Cortex/metabolism
MH  - Corpus Striatum/*metabolism
MH  - Dopamine/*metabolism
MH  - Homovanillic Acid/metabolism
MH  - Male
MH  - Nerve Tissue Proteins/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Recombinant Proteins/pharmacology
MH  - Rotation
PMC - PMC50547
EDAT- 1992/12/01 00:00
MHDA- 1992/12/01 00:01
PMCR- 1993/06/01
CRDT- 1992/12/01 00:00
PHST- 1992/12/01 00:00 [pubmed]
PHST- 1992/12/01 00:01 [medline]
PHST- 1992/12/01 00:00 [entrez]
PHST- 1993/06/01 00:00 [pmc-release]
AID - 10.1073/pnas.89.23.11347 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1992 Dec 1;89(23):11347-51. doi: 
      10.1073/pnas.89.23.11347.